• Treatment of attacks of hereditary angioedema (HAE).

Contraindicated in:

• None noted.

Use Cautiously in:

• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established in children.

GI: ↑ transaminases.

Local: injection site reactions.

Neuro: dizziness.

Misc: fever.

Drug-Drug:

• May ↓ antihypertensive response to ACE inhibitors.

(Generic available)

• Solution for injection: 10 mg/mL;

• SC (Adults): 30 mg may be repeated in 6 hr, not to exceed 3 injections/24 hr.

Firazyr

• Antagonizes the effects of bradykinin which are responsible for symptoms of HAE.

• Decreased manifestations of HAE including skin swelling, skin pain and abdominal pain with decreased progression to laryngeal edema.

Therapeutic Classification:hereditary angioedema agents

Pharmacologic Classification: bradykinin B2 receptor antagonists

Absorption: 97% absorbed following SUBQ administration.

Distribution: Unknown.

Metabolism/Excretion: Metabolized systemically by proteolytic enzymes to metabolites that are renally excreted; <10% excreted unchanged in urine.

Half-life: 1.4 hr.

(reduction of symptoms)

† 50% reduction in baseline symptoms.

• Instruct patient in recognizing symptoms of hereditary angioedema and correct technique for self-administration and disposal of equipment. Advise patient to read Patient Information before starting and with each Rx refill in case of changes.
• Caution patient to seek medical attention immediately after injection if laryngeal swelling occurs.
• May cause tiredness, drowsiness, and dizziness. Caution patient to avoid driving, and other activities requiring alertness until response to medication is known.
• Advise patient to notify health care professional if fever, dizziness, or rash occur.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

eye-KAT-i-bant

NDC Code^*

• 0093- Teva Pharmaceuticals USA, Inc.
  • 0093-3066- Icatibant
    • 0093-3066-34- 1 SYRINGE in 1 CARTON (0093-3066-34) > 3 mL in 1 SYRINGE

• 0093- Teva Pharmaceuticals USA, Inc.
  • 0093-3066- Icatibant
    • 0093-3066-93- 3 CARTON in 1 BOX (0093-3066-93) > 1 SYRINGE in 1 CARTON (0093-3066-19) > 3 mL in 1 SYRINGE

• 54092- Shire US Manufacturing Inc.
  • 54092-135- Firazyr
    • 54092-135-01- 1 SYRINGE, GLASS in 1 CARTON (54092-135-01) > 3 mL in 1 SYRINGE, GLASS

• 54092- Shire US Manufacturing Inc.
  • 54092-135- Firazyr
    • 54092-135-02- 3 SYRINGE, GLASS in 1 CARTON (54092-135-02) > 3 mL in 1 SYRINGE, GLASS

• 54092- Shire US Manufacturing Inc.
  • 54092-702- Firazyr
    • 54092-702-01- 1 SYRINGE, GLASS in 1 CARTON (54092-702-01) > 3 mL in 1 SYRINGE, GLASS

• 54092- Shire US Manufacturing Inc.
  • 54092-702- Firazyr
    • 54092-702-02- 1 SYRINGE, GLASS in 1 CARTON (54092-702-02) > 3 mL in 1 SYRINGE, GLASS

• 54092- Shire US Manufacturing Inc.
  • 54092-702- Firazyr
    • 54092-702-03- 3 SYRINGE, GLASS in 1 CARTON (54092-702-03) > 3 mL in 1 SYRINGE, GLASS